Cancer Research SABCS  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 35, 670-672, March 1, 1975]
© 1975 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kessel, D.
Right arrow Articles by Allen, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kessel, D.
Right arrow Articles by Allen, J.

Elevated Plasma Sialyltransferase in the Cancer Patient1

David Kessel2 and Janet Allen3

Departments of Oncology and Pharmacology, Wayne State University School of Medicine, and the Michigan Cancer Foundation, Detroit, Michigan 48201

Sialyltransferase activity was measured in plasma samples using desialated fetuin as the acceptor and cytidine 5'-phosphate-sialic acid as donor. The data show an increased enzyme level in 56 of 65 cancer patients studied, as compared with normal control values. The enzyme was not significantly elevated during lactation or in liver cirrhosis, but it was elevated in rheumatoid arthritis. Of the patients with cancer, 35 showed plasma enzyme levels above any value encountered in rheumatoid arthritis plasmas. The determinants of enzyme level in cancer appear to be complex; monitoring of plasma sialyltransferase may be of value in measuring tumor progression, metastatic involvement, or success of therapeutic programs.

1 Supported in part by NIH Grants CA 16053 and CA 07177.

2 Professor of Pharmacology and Oncology, Wayne State University School of Medicine, Detroit, Mich.

3 Summer Research Fellow from the Royal Free Hospital School of Medicine, University of London, London, England.

Received 9/ 9/74. Accepted 11/13/74.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
S. Kitazume, K. Nakagawa, R. Oka, Y. Tachida, K. Ogawa, Y. Luo, M. Citron, H. Shitara, C. Taya, H. Yonekawa, et al.
In Vivo Cleavage of {alpha}2,6-Sialyltransferase by Alzheimer {beta}-Secretase
J. Biol. Chem., March 4, 2005; 280(9): 8589 - 8595.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
C. Bauer, W. Reutter, K. Erhart, E Kottgen, and W Gerok
Decrease of human serum fucosyltransferase as an indicator of successful tumor therapy
Science, September 29, 1978; 201(4362): 1232 - 1233.
[Abstract] [PDF]


Home page
ScienceHome page
R. Bernacki and U Kim
Concomitant elevations in serum sialytransferase activity and sialic acid content in rats with metastasizing mammary tumors
Science, February 11, 1977; 195(4278): 577 - 580.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1975 by the American Association for Cancer Research.